FDA green light for Sarclisa combo in multiple myeloma
1st April 2021 Uncategorised 0CD38 inhibitor approved in combination with carfilzomib and dexamethasone More: FDA green light for Sarclisa combo in multiple myeloma Source: News
read moreCD38 inhibitor approved in combination with carfilzomib and dexamethasone More: FDA green light for Sarclisa combo in multiple myeloma Source: News
read moreExperts have raised ‘serious concerns’ over government plans for UK science funding More: Cancer research in the UK faces ‘perfect storm’ of funding cuts Source: News
read moreOpdivo plus Cabometyx doubled progression-free survival compared to those receiving Pfizer’s Sutent in a Phase III trial More: Opdivo plus Cabometyx approved in the EU for advanced renal cancer Source: News
read moreThe vaccine demonstrated 100% efficacy in a Phase III trial in adolescents aged 12 to 15 years old More: Positive results for Pfizer/BioNTech’s COVID-19 vaccine in 12-15 year olds Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals